Shree Ganesh Remedies Reports Q2 & H1FY27 Financial and Operational Performance
Shree Ganesh Remedies Ltd · Investor Presentation · 02 Nov 2026, 12:38 am
Shree Ganesh Remedies Reports Q2 & H1FY27 Financial and Operational Performance Shree Ganesh Remedies reported Q2FY27 revenue from operations of ₹23.29 crore, down 23% YoY but rebounding 62% QoQ. Operating EBITDA declined 59% YoY to ₹3.94 crore with EBITDA margins contracting 1,483 bps YoY to 16.9%, impacted by subdued European demand and input cost volatility. PAT fell 67% YoY to ₹1.63 crore. For H1FY27, revenue stood at ₹37.65 crore (-32% YoY) and PAT at ₹2.75 crore (-67% YoY). Growth catalysts include commercializing two pharma intermediates, expanding CRAMS pipelines, completing Block 7A construction, and phased Dahej expansion.
Original exchange filing (PDF)
More announcements from Shree Ganesh Remedies Ltd
- Transcript of Earnings Conference Call · 19 Nov 2026
- Audio Recording - Earnings Call held on November 14, 2026 · 15 Nov 2026
- Intimation for invitation of Earnings Conference Call · 14 Nov 2026
- Press Release · 02 Nov 2026
- Financial Results for quarter and half year ended September 30, 2026 · 01 Nov 2026
- Outcome of Board Meeting · 31 Oct 2026
- Shree Ganesh Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2026 ,inter alia, to consider and approve The Unaudited Financial .... · 31 Oct 2026
- Appointment of Company Secretary and Compliance Officer · 04 Oct 2026
